BeiGene, Ltd. (NASDAQ:BGNE) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNEGet Rating) have earned an average rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $286.43.

BGNE has been the subject of several research analyst reports. Morgan Stanley increased their price objective on shares of BeiGene from $295.00 to $325.00 and gave the company an “overweight” rating in a research report on Tuesday. Cowen raised their price target on shares of BeiGene from $200.00 to $213.00 in a research report on Thursday, November 10th. Daiwa Capital Markets began coverage on shares of BeiGene in a research report on Wednesday, January 11th. They set a “buy” rating and a $308.00 price target for the company. Guggenheim raised their price target on shares of BeiGene from $290.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday, January 20th. Finally, SVB Leerink lifted their target price on shares of BeiGene from $236.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, January 20th.

Insider Transactions at BeiGene

In related news, insider Xiaodong Wang sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $252.66, for a total value of $631,650.00. Following the sale, the insider now directly owns 5,512,556 shares in the company, valued at approximately $1,392,802,398.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO John Oyler sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $206.84, for a total value of $5,171,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Xiaodong Wang sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $252.66, for a total transaction of $631,650.00. Following the completion of the sale, the insider now owns 5,512,556 shares in the company, valued at $1,392,802,398.96. The disclosure for this sale can be found here. Insiders have sold a total of 43,033 shares of company stock worth $9,407,504 in the last quarter. Company insiders own 7.50% of the company’s stock.

Institutional Trading of BeiGene

A number of institutional investors and hedge funds have recently bought and sold shares of BGNE. Primecap Management Co. CA increased its stake in BeiGene by 17.5% during the third quarter. Primecap Management Co. CA now owns 4,734,979 shares of the company’s stock worth $638,370,000 after purchasing an additional 703,530 shares during the period. Pictet Asset Management SA grew its position in shares of BeiGene by 301.5% during the second quarter. Pictet Asset Management SA now owns 308,919 shares of the company’s stock worth $49,999,000 after buying an additional 231,976 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of BeiGene by 6.2% during the fourth quarter. Baillie Gifford & Co. now owns 3,408,719 shares of the company’s stock worth $749,714,000 after buying an additional 198,778 shares in the last quarter. Temasek Holdings Private Ltd grew its position in shares of BeiGene by 4.8% during the third quarter. Temasek Holdings Private Ltd now owns 3,109,970 shares of the company’s stock worth $419,286,000 after buying an additional 143,507 shares in the last quarter. Finally, Capital Group Private Client Services Inc. grew its position in shares of BeiGene by 74.2% during the first quarter. Capital Group Private Client Services Inc. now owns 275,197 shares of the company’s stock worth $51,902,000 after buying an additional 117,231 shares in the last quarter. 51.43% of the stock is currently owned by hedge funds and other institutional investors.

BeiGene Trading Down 0.8 %

NASDAQ BGNE opened at $266.75 on Wednesday. The company’s 50-day moving average price is $220.10 and its 200-day moving average price is $186.90. The company has a current ratio of 4.07, a quick ratio of 3.87 and a debt-to-equity ratio of 0.04. The stock has a market cap of $27.73 billion, a PE ratio of -12.49 and a beta of 0.78. BeiGene has a 12 month low of $118.18 and a 12 month high of $280.62.

BeiGene (NASDAQ:BGNEGet Rating) last issued its earnings results on Wednesday, November 9th. The company reported ($5.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.02) by ($1.37). BeiGene had a negative return on equity of 38.92% and a negative net margin of 171.94%. The business had revenue of $387.63 million for the quarter, compared to the consensus estimate of $360.25 million. Equities research analysts forecast that BeiGene will post -18.27 earnings per share for the current year.

About BeiGene

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

See Also

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.